Cure My Disease

Don't miss your cure!

 Log in / Sign up

New mRNA drug takes on HER2 cancers in first human trial

NCT ID NCT07334119

Recruiting now Disease control Sponsor: Myeloid Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. About 60 participants will receive the drug every two weeks and be closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MT-304 (mRNA therapy) and nivolumab
What this could lead to
If it works, this could point toward a new treatment option for advanced HER2-expressing cancers.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so safety and dosing are still being figured out. It may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 EXPRESSING SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Biliary Tract Neoplasms breast neoplasm Carcinoma, Ovarian Epithelial cholangiocarcinoma colorectal neoplasm endometrium neoplasm non-small cell lung carcinoma transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2 EXPRESSING SOLID TUMORS

Contacts and locations

Locations

  • Cabrini Health

    RECRUITING

    Melbourne, Victoria, 3144, Australia

  • Calvary Mater Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Cancer Research SA Pty Ltd

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Icon Cancer Centre South Brisbane

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Scientia Clinical Research Ltd

    RECRUITING

    Randwick, New South Wales, 2031, Australia

    Contact Email: •••••@•••••

  • The Kinghorn Cancer Centre

    RECRUITING

    Darlinghurst, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.